Crinetics Pharmaceuticals Inc. (CRNX)’s Financial Results Comparing With Melinta Therapeutics Inc. (NASDAQ:MLNT)

As Biotechnology companies, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Melinta Therapeutics Inc. (NASDAQ:MLNT) are our subject to contrast. And more specifically their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals Inc. 23 251.13 N/A -1.27 0.00
Melinta Therapeutics Inc. 4 0.41 N/A -15.68 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Crinetics Pharmaceuticals Inc. and Melinta Therapeutics Inc.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals Inc. 0.00% -27% -20.8%
Melinta Therapeutics Inc. 0.00% -71.6% -32.3%

Liquidity

The current Quick Ratio of Crinetics Pharmaceuticals Inc. is 18 while its Current Ratio is 18. Meanwhile, Melinta Therapeutics Inc. has a Current Ratio of 1.4 while its Quick Ratio is 1.1. Crinetics Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Melinta Therapeutics Inc.

Analyst Recommendations

In next table is delivered Crinetics Pharmaceuticals Inc. and Melinta Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Crinetics Pharmaceuticals Inc. 0 0 1 3.00
Melinta Therapeutics Inc. 0 0 0 0.00

Crinetics Pharmaceuticals Inc.’s upside potential currently stands at 127.27% and an $40 average target price. Melinta Therapeutics Inc. on the other hand boasts of a $14 average target price and a 372.97% potential upside. Based on the analysts belief we can conclude, Melinta Therapeutics Inc. is looking more favorable than Crinetics Pharmaceuticals Inc.

Institutional & Insider Ownership

Roughly 97.6% of Crinetics Pharmaceuticals Inc. shares are held by institutional investors while 24.3% of Melinta Therapeutics Inc. are owned by institutional investors. Insiders held 5.65% of Crinetics Pharmaceuticals Inc. shares. On the other hand, insiders held about 0.3% of Melinta Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Crinetics Pharmaceuticals Inc. -16.58% -18.91% -21.15% -18.03% -20.72% -32.38%
Melinta Therapeutics Inc. -1.73% -43.69% -5.92% -4.34% -84.58% 0.16%

For the past year Crinetics Pharmaceuticals Inc. has -32.38% weaker performance while Melinta Therapeutics Inc. has 0.16% stronger performance.

Summary

Crinetics Pharmaceuticals Inc. beats on 7 of the 9 factors Melinta Therapeutics Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.